← Back to Clinical Trials
Recruiting NCT06501222

NCT06501222 The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06501222
Status Recruiting
Phase
Sponsor Yuanjun Yang
Condition Chronic Kidney Diseases
Study Type INTERVENTIONAL
Enrollment 114 participants
Start Date 2024-03-01
Primary Completion 2026-03-30

Trial Parameters

Condition Chronic Kidney Diseases
Sponsor Yuanjun Yang
Study Type INTERVENTIONAL
Phase N/A
Enrollment 114
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-03-01
Completion 2026-03-30
Interventions
Remote ischemic conditioning

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The incidence of Chronic kidney disease (CKD) is showing an upward trend, but the therapeutic effect of treatment is limited. Remote ischemic conditioning (RIC) has the potential to safeguard remote organs via the repeated application of brief ischemic stimuli. the aim of our study is to investigate whether RIC can protect the renal function in patients with CKD.

Eligibility Criteria

Inclusion Criteria: 1. CKD Patients with eGFR ≥ 15ml/min/1.73m2 2. Age ≥ 18 years old 3. 24-hour urine protein excretion ≤ 3.5g 4. Subjects who have signed the informed consent form Exclusion Criteria: 1. Patients with nephrotic syndrome 2. Patients with acute kidney injury 3. Patients who have undergone renal replacement treatment in the past 4. Patients who may have medication changes during RIC or sham-RIC intervention 5. Patients with a history of diabetes or glycated hemoglobin \> 8% 6. Patients with familial hypercholesterolemia (\>5.5 mmol/L) accompanied by high low-density lipoprotein (\>2.5 mmol/L) 7. Patients with contraindications to RIC, such as vascular injury, soft tissue injury, fracture, infection, or known peripheral vascular disease in both arms 8. Patients with a history of hemostatic disorders, systemic bleeding, or thrombocytopenia 9. Patients with cardiogenic embolism (atrial fibrillation) or other severe arrhythmias (severe bradycardia, third-degree atrioventricu

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology